We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for asciminib hydrochloride (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
asciminib hydrochloride
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
film-coated tablets
Indication
For the treatment of patients 18 years of age and above with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
Therapeutic area
Haematology